ChiCTR-PRC-16010054 版本V1.0 版本创建时间2017/01/14 09:15:42 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-PRC-16010054 

最近更新日期:

Date of Last Refreshed on:

2016-11-30 17:07:44 

注册时间:

Date of Registration:

2016-11-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

外周血血常规及血生化检测指标对局部晚期非小细胞肺癌放疗疗效的预测价值

Public title:

blood routine examination and serum biochemical indexes Does Lymphocyte-to-Monocyte Ratio Before, During, or After Definitive Chemoradiation for Locally Advanced Pancreatic Cancer Predict for Clinical Outcomes

注册题目简写:

English Acronym:

研究课题的正式科学名称:

外周血血常规及血生化检测指标对局部晚期非小细胞肺癌放疗疗效的预测价值

Scientific title:

blood routine examination and serum biochemical indexes Does Lymphocyte-to-Monocyte Ratio Before, During, or After Definitive Chemoradiation for Locally Advanced Pancreatic Cancer Predict for Clinical Outcomes

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周建国 

研究负责人:

马虎 

Applicant:

Jian-Guo Zhou 

Study leader:

Hu Ma 

申请注册联系人电话:

Applicant telephone:

+86 18311543939

研究负责人电话:

Study leader's
telephone:

+86 18311543939

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jianguo.zhou@yahoo.com

研究负责人电子邮件:

Study leader's E-mail:

mahuab@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省遵义市大连路149号

研究负责人通讯地址:

贵州省遵义市大连路149号

Applicant address:

149 Dalian Road, Zunyi, Guizhou, China

Study leader's address:

149 Dalian Road, Zunyi, Guizhou, China

申请注册联系人邮政编码:

Applicant postcode:

563000

研究负责人邮政编码:

Study leader's postcode:

563000

申请人所在单位:

遵义医学院附属医院

Applicant's institution:

Affiliated hospital of Zunyi Medical University

研究负责人所在单位:

遵义医学院附属医院

Affiliation of the Leader:

Affiliated hospital of Zunyi Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016年遵医伦审第(1)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

遵义医学院附属医院伦理委员会

Name of the ethic committee:

The ethics committee of Affiliated hospital of Zunyi Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2016-01-08 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

遵义医学院附属医院

Primary sponsor:

Affiliated hospital of Zunyi Medical University

研究实施负责(组长)单位地址:

贵州省遵义市大连路149号

Primary sponsor's address:

149 Dalian Road, Zunyi, Guizhou, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

遵义市

Country:

China

Province:

Guizhou

City:

Zunyi

单位(医院):

遵义医学院附属医院

具体地址:

贵州省遵义市大连路149号

Institution
hospital:

Affiliated hospital of Zunyi Medical University

Address:

149 Dalian Road, Zunyi, Guizhou, China

经费或物资来源:

国家自然科学基金、贵州省科技厅项目

Source(s) of funding:

This work was supported by NSFC (Natural Science Foundation of China) (81360351), Start-Up Fund for Doctor of Zunyi Medical University and the Department of Science and Technology of Guizhou Province

研究疾病:

局部晚期非小细胞肺癌  

Target disease:

local advanced NSCLC

研究疾病代码:

Target disease code:

研究类型:

预后研究

Study type:

Prognosis study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

通过回顾性分析探讨不同外周血血常规及血生化检测指标对局部晚期非小细胞肺癌放疗的疗效预测价值  

Objectives of Study:

Through the retrospective analysis to explore different peripheral blood routine and blood biochemical examination indexes for locally advanced non-small cell lung cancer radiotherapy curative effect prediction value

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、放疗前采血的患者
2、年龄18-80岁
3、诊断明确的肺癌,IIIA期及IIIB期

Inclusion criteria

1. before radiotherapy patients blood;
2. aged 18 to 80 years old;
3. clear lung cancer diagnosis, stage IIIA, IIIB.

排除标准:

1、不能全部完成放疗的患者

Exclusion criteria:

can't complete radiotherapy patients

研究实施时间:

Study execute time:

From 2016-12-03 00:00:00 To 2017-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-12-05 00:00:00 To 2017-05-01 00:00:00

干预措施:

Interventions:

组别:

2

样本量:

80

Group:

2

Sample size:

干预措施:

外周血指标

干预措施代码:

Intervention:

blood test

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州 

市(区县):

遵义市 

Country:

china

Province:

Guizhou

City:

Zunyi

单位(医院):

遵义医学院附属医院 

单位级别:

三甲 

Institution
hospital:

Level of the institution:

测量指标:

Outcomes:

指标中文名:

无进展生存期

指标类型:

主要指标

Outcome:

PFS

Type:

Primary indicator

测量时间点:

测量方法:

随访

Measure time point of outcome:

Measure method:

follow-up

指标中文名:

总生存期

指标类型:

主要指标

Outcome:

OS

Type:

Primary indicator

测量时间点:

测量方法:

随访

Measure time point of outcome:

Measure method:

follow-up

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 12 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机研究

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-randomed

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

非随机研究

Blinding:

Non-randomed

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2018年12月

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Dec 2018

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-11-30 17:07:44